Nuvocid (oritavancin) / Melinta Therap, Novartis, Menarini - LARVOL DELTA

Oritavancin as salvage therapy for refractory vertebral osteomyelitis: a case report (ESCMID Global 2026) - No abstract available

Case report • Clinical • Inflammation

Pharmacokinetic estimation analysis of multi-dose oritavancin for prolonged durations of therapy (ESCMID Global 2026) - No abstract available

PK/PD data

Real-world use of oritavancin for Gram-positive infections in Spain: the ORIUSE study (ESCMID Global 2026) - No abstract available

Clinical • Gram positive • Real-world • Real-world evidence • Infectious Disease

Proportion and antibiogram of methicillin-resistant Staphylococcus aureus (MRSA) in Africa: a systematic review and meta-analysis. (PubMed, Antimicrob Resist Infect Control) - "The proportion of MRSA in Africa remains high at 42.2%, with marked regional disparities. Although resistance rates for linezolid and vancomycin are relatively low, they surpass global averages, raising concerns about emerging resistance. Alarmingly high resistance rates to several other antibiotics further underscore the urgent need for targeted interventions and continuous surveillance."

Journal • Retrospective data • Infectious Disease

Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome? (PubMed, J Antimicrob Chemother) - "Long-acting glycopeptide antibiotics (LGPs), such as dalbavancin and oritavancin, are a novel class of antibiotic agents effective in the treatment of Gram-positive infections. These include high upfront costs, cost siloing, impractical and inconsistent medication approval processes and limited integration into existing multidisciplinary models of care. There is a clear need to improve funding arrangements, institutional workflows and models of care to promote safe and equitable access to LGPs, in line with processes developed for other high-cost medications."

Journal • Review • Infectious Disease

Cardiac Implantable Electronic Device-Related Infective Endocarditis Caused by Bacillus cereus: A Case Report. (PubMed, J Clin Med) - "Standard empirical therapy covering methicillin-resistant Staphylococci and Gram-negative bacteria was administered, including oritavancin and gentamicin...To eradicate bacteria in the gastrointestinal tract, oral vancomycin (125 mg 4 times a day) was added...However, the long half-life lipoglycopeptide antibiotic, oritavancin, administered weekly, proved effective in treating CIED-IE. Infection with rare or opportunistic microorganisms may require extended microbiological diagnostics and non-standard antibiotic therapy; therefore, the medical history should consider risk factors for such infections."

Journal • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

Could oritavancin be a promising alternative treatment for staphylococcal bone and joint infections? Insights from the determination of oritavancin minimum inhibitory concentrations in a collection of clinical isolates from the French National reference centre for staphylococci. (PubMed, Eur J Clin Microbiol Infect Dis) - "Although oritavancin showed lower overall activity than dalbavancin, resistance to oritavancin could not be reliably inferred from the activity of related antibiotics. This lack of cross-resistance highlights the need for dedicated phenotypic susceptibility testing prior to clinical use."

Journal • Infectious Disease

Mechanistic insight into the role of lipoglycopeptide drugs in hepatotoxicity. (PubMed, Biochim Biophys Acta Biomembr) - "This work compares two clinically important glycopeptide antibiotics, Teicoplanin and Oritavancin, using an integrative approach that combines in vivo pathology, lipid biophysics, drug-lipid interactions by NMR spectroscopy, and molecular dynamics simulations. These findings demonstrate that glycopeptide-induced hepatotoxicity is governed by the topology and duration of membrane interactions rather than simply by their magnitude. The study promotes a lipid-centric framework for the logical development of safer, membrane-active treatments and emphasises the value of lipid membrane models and atomistic simulations as predictive tools in early-stage drug evaluation."

Journal

The UK Antimicrobial Registry (UKAR): an overview of the first 20 months of recruitment. (PubMed, JAC Antimicrob Resist) - "UKAR is an ongoing prospective registry of adult inpatients prescribed 11 eligible study drugs (cefiderocol, ceftaroline, ceftazidime/avibactam, ceftobiprole, ceftolozane/tazobactam, dalbavancin, delafloxacin, eravacycline, imipenem/cilastatin/relebactam, meropenem/vaborbactam and oritavancin). The UKAR provides real-world data on the use of novel antimicrobials confirming they are sometimes used empirically as well as for directed therapy to treat both complex and common infections, and often for multiresistant pathogens. The study is a novel and important resource to support the judicious use of these drugs."

Journal • Critical care • Infectious Disease • Nephrology • Respiratory Diseases • Septic Shock

Lipoglycopeptides Unleashed: The Power of Dalbavancin and Oritavancin (ASHP 2025) - No abstract available

Sodium load of novel antibiotics: considerations for nephrologists and clinicians. (PubMed, Int Urol Nephrol) - "Parenteral antibiotics are an often-overlooked contributor to sodium intake. Clinicians should be aware of this hidden source in sodium-sensitive patients such as kidney disease patients. We propose a visual chart to support sodium-conscious antimicrobial selection as part of broader stewardship strategies."

Journal • Review • Chronic Kidney Disease • Nephrology • Renal Disease

Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections (clinicaltrials.gov) - P1 | N=41 | Completed | Sponsor: Melinta Therapeutics, LLC | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pediatrics

Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review. (PubMed, Antibiotics (Basel)) - "Background: Dalbavancin and oritavancin are long-acting lipoglycopeptides increasingly used off-label for a variety of Gram-positive infections. This systematic review was registered on Open Science Framework. This work was supported by grants from the Italian Ministry of Health through Ricerca Corrente, Linea 3, Progetto 3."

Journal • Review • Cardiovascular • Infectious Disease • Inflammation

ML-ORI-201: Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections (clinicaltrials.gov) - P2 | N=118 | Completed | Sponsor: Melinta Therapeutics, LLC | Recruiting ➔ Completed | N=75 ➔ 118

Enrollment change • Trial completion • Dermatology • Infectious Disease • Pediatrics • CRP

Difficult-to-Treat Skin and Soft Tissue Infections Caused by Panton-Valentine Leukocidin-Producing Community-Associated Methicillin-Resistant Staphylococcus aureus: A Case Series. (PubMed, Infect Dis Rep) - "Long-acting lipoglycopeptides (oritavancin or dalbavancin) were evaluated as therapeutic options to achieve clinical resolution. PVL-positive CA-MRSA infections are characterized by recurrence, intrafamilial clustering, and frequent therapeutic failure with standard oral agents. Effective management requires an integrated approach combining prompt surgical drainage; systemic therapy, preferably including long-acting lipoglycopeptides; and comprehensive decolonization of all close contacts."

Journal • Infectious Disease

Oritavancin for Treatment of Osteomyelitis: A Systematic Review and Meta-Analysis of Observational Studies. (PubMed, Pharmacotherapy) - "Despite previous warnings, we found no evidence of ineffectiveness with ORI for OM. ORI's infrequent dosing schedule may provide convenience over daily parenteral therapy, particularly for difficult-to-treat pathogens like MRSA and VRE. Further research is needed to optimize dosing strategies based on pathogen susceptibility and establish appropriate therapeutic drug monitoring protocols."

Journal • Observational data • Retrospective data • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics

Comparative Analysis of Adverse Drug Reactions Between Oritavancin Diphosphate and Oritavancin-HPβCD Using FAERS Data. (PubMed, Hosp Pharm) - "Oritavancin, a lipoglycopeptide antibiotic, has emerged as a treatment alternative to vancomycin, especially in light of rising resistance. Both formulations are considered safe, consistent with their product information. These findings highlight the need for formulation-specific safety considerations and standardized protocols in clinical practice."

Adverse drug reaction • Journal • Dermatology • Immunology • Infectious Disease • Movement Disorders • Pediatrics • Pruritus • Urticaria

Oritavancin in LVAD related infections - a chance for shortening therapy and improving outcomes. (PubMed, BMC Infect Dis) - No abstract available

Journal • Infectious Disease

In vitro and in vivo efficacy of vancomycin against Elizabethkingia species and the impact of increased vancomycin MICs. (PubMed, Microbiol Spectr) - "Vancomycin improved Galleria mellonella survival in a dose-dependent manner, whereas teicoplanin, dalbavancin, oritavancin, and daptomycin were ineffective...Most commonly considered agents, including fluoroquinolones, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole, are increasingly compromised by resistance, toxicity, or inconsistent efficacy...These findings suggest vancomycin may offer therapeutic benefit when no preferred options are available. They support cautious use in selected cases and highlight the need for continued monitoring of susceptibility and resistance development."

Journal • Preclinical • Infectious Disease

ORItavancin as a therapeutic regimen for Cardiac Implantable Electronic Devices infections with multidrug-resistant Gram-positive cocci (ORI-4-CIEDi) pilot study: rationale and design. (PubMed, Cardiol J) - No abstract available

Journal • Cardiovascular • Dermatology • Infectious Disease

Medical Source Control with Oritavancin in Complicated Gram-positive Bacterial Infections: A Case Series. (PubMed, Int J Infect Dis) - "These findings suggest it may serve as an effective medical alternative to source control in frail, difficult-to-treat populations."

Journal • Infectious Disease

ML-ORI-201: Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: Melinta Therapeutics, LLC | N=200 ➔ 75

Enrollment change • Dermatology • Infectious Disease • Pediatrics • CRP

Emerging Antimicrobial Strategies Against Heterogeneous and Vancomycin-Intermediate Staphylococcus aureus. (PubMed, Int J Gen Med) - "Conventional monotherapies, including daptomycin and linezolid, are often compromised by cross-resistance and inconsistent efficacy...Novel antimicrobials, such as next-generation glycopeptides (LY333328, oritavancin, YV4465), synthetic agents (pyridyl disulfides, alpha-amyrin), and natural derivatives (plant flavonoids, cyanobacterial metabolites), have demonstrated enhanced activity against VISA/hVISA by disrupting membranes, suppressing virulence, or reversing resistance...Despite these promising advances, clinical translation remains challenging, requiring rigorous validation of synergistic mechanisms, optimized dosing strategies, and resistance mitigation approaches. Continued innovation in antimicrobial development is essential to address the growing threat of multidrug-resistant Staphylococcus aureus infections."

Heterogeneity • Journal • Review • Infectious Disease

Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review. (PubMed, Pharmaceuticals (Basel)) - "In vitro data demonstrated strong activity of oritavancin against methicillin-resistant Staphylococcus aureus and S. epidermidis biofilms, particularly in synergy with rifampin. Oritavancin represents a promising adjunct or alternative to conventional antimicrobial regimens in PJIs, particularly for outpatient management or in patients with multidrug-resistant Gram-positive infections. Further prospective studies are needed to define its role, optimal dosing, and long-term efficacy in this complex clinical setting."

Journal • Review • Infectious Disease • Orthopedics

A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges? (PubMed, Infect Dis Ther) - "Both agents share broad-spectrum activity against multidrug-resistant pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant strains, yet differ markedly in pharmacokinetics, pharmacodynamics, resistance profiles, and clinical adoption. Furthermore, we explore resistance development, drug-drug interaction profiles, and outpatient utility, providing actionable insights for optimizing treatment strategies. These findings underscore the need for tailored clinical integration of dalbavancin and oritavancin and spotlight their potential roles in future antimicrobial stewardship frameworks."

Journal • Review • Cardiovascular • Infectious Disease • Inflammation